The Saudi Arabia Biosensors Market was valued at $164.9 Million in 2025 and projected to reach to $238.6 Million by 2030, representing a compound annual growth rate of CAGR 7.7%. Saudi Arabia's biosensors market is poised for sustained growth through 2030, supported by government healthcare modernization programs and increased private sector investment in medical diagnostics.
Saudi Arabia's biosensors market is valued at $164.9 million in 2025, with a projected CAGR of 7.7% through 2030, reaching $238.6 million. This growth outpaces several regional peers, driven by strategic healthcare modernization initiatives.
Saudi Arabia's Vision 2030 agenda prioritizes healthcare infrastructure development, with significant government investments in diagnostic capabilities and medical technology adoption, creating favorable conditions for biosensor market expansion.
Rising demand for rapid, decentralized diagnostic solutions in Saudi Arabia's healthcare system is accelerating biosensor adoption across hospitals, clinics, and remote healthcare facilities, particularly for chronic disease management.
Saudi Arabia is emerging as a key biosensor adoption hub in the GCC region, with increasing local manufacturing partnerships, regulatory framework development, and growing awareness among healthcare providers and patients.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | SENSOR PATCHES (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 9.5% from 2025 to 2030 |
| Largest Segment | EMBEDDED DEVICES (Type) |
| Market Size Base Year (Billions) | ~USD 34.54 (2025) |
| Revenue Forecast (Billions) | ~USD 54.37 (2030) |
| Segments Covered | Type, Product, Application, Technology |
4 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| TSI INC | China | Public Company | Tsingtao Beer (core and premium variants),Laoshan Beer,Hans Beer and other regional beers, |
| X-FAB | Germany | Public Company | Analog/Mixed-Signal Foundry (incl. automotive, industrial, consumer),MEMS and Sensor Platforms,Power (SiC, GaN, and related) and Silicon Photonics, |
| LENOVO | China | Public Company | Small form factor / desktop PCs as signage players,Embedded / dedicated media players and thin clients,Tablets and smart devices as kiosks / POS displays, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and bioproduction solutions),Life Sciences (genomics, analytical instruments, and research tools),Diagnostics (clinical instruments, consumables, and software), |
| ABBOTT LABORATORIES | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| MEDTRONIC | Ireland | Public Company | Cardiovascular Portfolio,Neuroscience Portfolio,Medical Surgical Portfolio, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Instruments and Systems,Life Science Reagents and Consumables, |
| DUPONT | United States | Public Company | Healthcare & Water Technologies,Protective Materials and Medical Packaging (TYVEK),Construction Solutions (TYVEK house wrap, STYROFOAM, CORIAN), |
| BIOSENSORS INTERNATIONAL GROUP, LTD. | Singapore | Private Company | Interventional Cardiology (DES, BMS, balloons, catheters),Critical Care (pressure transducers, CVCs, PA catheters, pacing, embolectomy),Cardiac Diagnostic (imaging and clinical applications), |
| DEXCOM, INC. | United States | Public Company | Dexcom G7 and G7 15 Day,Dexcom G6,Dexcom ONE+ and value-focused CGM, |
| MASIMO | United States | Private Company | SET and Rainbow SET pulse oximetry (including sensors and OEM),Brain function and hemodynamic monitoring,Hospital automation and connectivity (Patient SafetyNet, Iris, iSirona, Replica, UniView), |
| UNIVERSAL BIOSENSORS | Australia | Public Company | PT/INR coagulation strips and Xprecia devices,Sentia wine testing products,Laboratory and coagulation testing services, |
TSI Inc is a publicly traded company founded in 1903 and headquartered in China, employing 29,257 people. The company operates as a significant industrial enterprise with a long-established presence in its market.
X-FAB is a publicly traded semiconductor manufacturer founded in 1992 and headquartered in Germany, employing 4,300 people. The company specializes in analog and mixed-signal semiconductor fabrication services.
Lenovo is a publicly traded technology company founded in 1984 and based in China, operating as a major global manufacturer of computing devices and IT solutions.
Danaher Corporation is a publicly traded American conglomerate founded in 1969, employing 59,000 people across diversified business segments including life sciences, diagnostics, and environmental solutions.
Abbott Laboratories is a publicly traded pharmaceutical and healthcare company founded in 1888 and headquartered in the United States, employing 115,000 people globally. The company develops and manufactures pharmaceuticals, diagnostics, nutritional products, and medical devices.
Medtronic is a publicly traded medical technology company founded in 1949 and headquartered in Ireland, employing 95,000 people. The company develops and manufactures medical devices and therapies across multiple healthcare specialties.
Bio-Rad Laboratories, Inc. is a publicly traded company founded in 1952 and based in the United States, employing 7,450 people. The company manufactures and distributes life science research products and clinical diagnostics solutions.
DuPont is a publicly traded chemical and materials company founded in 2015 and headquartered in the United States, employing 15,000 people. The company produces specialty chemicals, advanced materials, and industrial solutions.
Biosensors International Group, Ltd. is a private medical device company founded in 1990 and based in Singapore, employing 312 people. The company specializes in the development and manufacture of interventional cardiology devices.
Dexcom, Inc. is a publicly traded medical technology company founded in 1999 and based in the United States, employing 11,050 people. The company specializes in continuous glucose monitoring systems for diabetes management.
Masimo is a privately held medical technology company founded in 1989 and based in the United States, employing 2,200 people. The company develops and manufactures noninvasive monitoring technologies and sensors.
Universal Biosensors is a publicly traded diagnostics company founded in 2001 and based in Australia, employing 76 people. The company develops and manufactures rapid diagnostic test devices.
Rest Of GCC Countries biosensors market is estimated at $164.9 million in 2025, with verified data confirming this valuation from KS table sources.
Rest Of GCC Countries biosensors market is forecasted to reach $238.6 million by 2030, representing growth from the 2025 baseline.
Rest Of GCC Countries biosensors market is expected to grow at a compound annual growth rate of 7.7% between 2025 and 2030.
Rest Of GCC Countries biosensor growth is driven by healthcare modernization, increased R&D investments, rising demand for point-of-care diagnostics, and digital health infrastructure expansion.
Rest Of GCC Countries is seeing accelerated adoption in healthcare diagnostics, environmental monitoring, and industrial applications, with point-of-care solutions leading growth.
The study involved major activities in estimating the current size of the biosensors market. Exhaustive secondary research was done to collect information on biosensors. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the biosensor.
Various secondary sources were referred to in the secondary research process to identify and collect information relevant to this study. Secondary sources included annual reports, press releases, and investor presentations of companies; white papers, certified publications, and articles from recognized authors; directories; and databases. Secondary research was mainly carried out to obtain critical information about the industry’s supply chain, value chain, the pool of key players, and market classification and segmentation according to industry trends, geographic markets, and key developments from both market- and technology-oriented perspectives. Secondary sources included corporate filings (such as annual reports, investor presentations, and financial statements); trade, business, and professional associations; white papers; IoT technologies journals and certified publications; articles by recognized authors; gold- and silver-standard websites; directories; and databases. Data was also collected from secondary sources, such as the Semiconductor Industry Association, Global Semiconductor Alliance, and Taiwan Semiconductor Industry Association.
Secondary research was mainly used to obtain critical information about the industry's supply chain and value chain, the total pool of key players, market classification and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments from both the market and technology-oriented perspectives. Secondary data has been gathered and analyzed to determine the overall market size, which has also been validated by primary research.
Extensive primary research was conducted after understanding and analyzing the current scenario of the biosensors market through secondary research. Primary interviews were held with key opinion leaders from the demand and supply sides in four key regions: North America, Europe, Asia Pacific, and the rest of the world. Nearly 25% of the primary interviews were held with the demand side and 75% with the supply side. The primary data was gathered primarily through telephonic interviews, which were 80% of the total primary interviews. Surveys and e-mails were also utilized to gather data.
Note: Three tiers of companies are defined based on their total revenue as of 2024; tier 1: revenue more than or equal to USD 500 million, tier 2: revenue between USD 100 million and USD 500 million, and tier 3: revenue less than or equal to USD 100 million. Other designations include sales and marketing executives, researchers, and members of various biosensor organizations.
To know about the assumptions considered for the study, download the pdf brochure
In this report, both the top-down and bottom-up approaches were implemented to estimate and validate the size of the biosensors market and various other dependent submarkets. Secondary research identified key players in this market, and their market shares in the respective regions were determined through primary and secondary research.
This entire research methodology included the study of annual and financial reports of top companies, as well as interviews with experts (such as CEOs, VPs, directors, and marketing executives) for key insights (both quantitative and qualitative). All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All the possible parameters that affect the market covered in this research study were accounted for, viewed in detail, verified through primary research, and analyzed to obtain the final quantitative and qualitative data. This data was consolidated and supplemented with detailed inputs and analysis from MarketsandMarkets and presented in this report. The figures below show the overall market size estimation process employed for this study.
Bottom-Up Approach
Top-Down Approach

After arriving at the overall size of the biosensors market from the estimation process explained above, the market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed (wherever applicable) to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. The biosensors market size was validated using both top-down and bottom-up approaches.
Biosensors are semiconductor devices designed to detect biological responses using transducers that convert these responses into electrical signals. They achieve this by combining a biological recognition element (bioreceptor) with a physicochemical transducer. The bioreceptor specifically interacts with a particular biological analyte. The transducer then converts this interaction into a measurable signal, such as an electrical current, optical change, mass change, or thermal signal, which relates to the analyte’s concentration. Common bioreceptors include enzymes, antibodies, nucleic acids, cells, or microorganisms. They are used as analytical tools to deliver qualitative or quantitative results in detecting protein or nucleic acid targets.
With the market data given, MarketsandMarkets offers customizations according to the company’s specific needs. The following customization options are available for the report:
Full forecast, segment splits, and company analysis for all Biosensors Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report